Introduction {#Sec1}
============

Coronavirus disease 2019 (COVID-19), the new pandemic caused by coronavirus 2 (SARS-COV-2), has heavily affected the population worldwide since first recognized in December 2019 in Wuhan, China \[[@CR1]\]. The disease follows a very heterogenous course, where the vast majority of patients are asymptomatic or experience few and mild symptoms, while others experience a very aggressive clinical course and progress rapidly to severe acute lung injury and acute respiratory distress syndrome, often associated with multiorgan failure (MOF) \[[@CR2]\].

Evidence is gathering on the double-faceted role of the immune system in SARS-CoV-2 infection. An intact immune response is needed to face the initial infection and clear the virus, with patients recovering from the infection demonstrating evidence of humoral neutralizing antibodies \[[@CR3]\]. On the other hand, the severity of COVID-19 and MOF occurrence seem to be related to clinical and laboratory parameters of inflammatory response (lymphopenia, hypoalbuminemia, higher levels of alanine aminotransferase, lactate dehydrogenase, C-reactive protein, ferritin, and D-dimer) and markedly higher levels of proinflammatory cytokines (interleukin-2 receptor, IL6, IL-10, and tumor necrosis factor-α) \[[@CR4]\]. On these grounds, therapies targeting inflammation (e.g., IL6/IL6R antibodies or steroids) have been used and shown potential benefit in full-blown COVID-19 patients \[[@CR5]\].

Symptomatic disease and severe disease manifestations are more prevalent in elderly and co‐morbid individuals \[[@CR6]\]. The role of concomitant cancer, particularly for hematologic malignancies, remains unclear \[[@CR7]--[@CR10]\], with initial evidence suggesting an increased risk of infection and of experiencing a rapid disease course in patients with cancer \[[@CR6]\]. Studies from China have reported a statistically higher incidence of severe events (including intensive care unit admission/ventilation/death) in infected individuals with cancer compared to those without. Moreover, in a recent series focused on patients with hematologic neoplasms hospitalized for COVID-19, those without active cancer (watch & wait strategy and remission status) presented a favorable outcome \[[@CR11]\]. In that cohort, six out of six patients diagnosed with chronic lymphocytic leukemia (CLL) survived the infection \[[@CR11]\]. A similarly favorable outcome was reported in a Spanish cohort focusing on patients with CLL, where all four affected cases recovered from COVID-19 without intensive care admission \[[@CR12]\]. Besides this report, only anecdotal CLL cases have been reported so far \[[@CR13]\].

CLL is a paradigmatic example of malignancy associated with impaired immune responses to common pathogens in a context of a profound immune dysregulation reflected by hypogammaglobulinemia, qualitative and quantitative B- and T-cell defects, including impaired response to vaccination, and CD4^+^ lymphopenia, as well innate immune dysfunction and neutropenia \[[@CR14], [@CR15]\]. This can be further exacerbated by antileukemic treatments that by definition impact on the host immune system, some applied continuously until progression \[[@CR16]\]. This could arguably compromise the capacity of patients with CLL to clear the virus, with a possible higher infection risk for this population. Conversely, immunodeficiency might as well be protective against severe COVID-19 and MOF, limiting excessive activation of the immune system. In this context, the role of novel targeted therapies such as Bruton tyrosine kinase (BTK) inhibitors, with overall anti-inflammatory activity due to effects on both innate immune cells and platelets, has also been proposed as potentially beneficial against severe disease manifestations \[[@CR17]\]. Nevertheless, patients with CLL tend to be elderly and carry several comorbidities, representing, in principle, prototypic patients who may suffer the most severe consequences of a SARS-CoV-2 infection.

Limited data are currently available on the clinical course of COVID-19 patients with CLL and the potential impact of antileukemic treatment on the severity and outcome of COVID-19. Thus, we undertook this retrospective international multicenter study in order to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome.

Materials and methods {#Sec2}
=====================

Data collection {#Sec3}
---------------

This is a retrospective international multicenter study of the European Research Initiative on CLL (ERIC) and the CLL Campus. Participating members received a survey during the COVID-19 pandemic, using a cloud-based online platform. Investigators who confirmed patients with CLL and COVID-19 in their patient cohort were asked to fill a template with relevant clinical information. The study was approved by the institutional ethics committee, informed consent was obtained from all subjects. Data collection took place between March 28 and May 22, 2020. The full list of participating countries is reported in Supplementary Table [1](#MOESM1){ref-type="media"}.

Data extracted from the medical records included: baseline demographics, date of CLL diagnosis, CLL treatment status, presence, number, and type of comorbidities, date of COVID-19, COVID-19 symptoms, COVID-19 management, treatment, and outcome. Of the 190 patients studied, four Spanish cases were previously published in extenso \[[@CR12]\], 47 patients were included in a report describing the impact of SARS-CoV-2 pandemic infection on the practical management of CLL in Italy with only limited clinical data \[[@CR18]\].

Overall survival (OS) was defined as the time from suspected COVID-19 to death or last follow-up date.

In keeping with international practice, patients were deemed to have COVID-19 if an RT-PCR assay test from a throat or nose swab was positive for SARS-CoV-2. Patients with only radiological or clinical suspicion of COVID-19 yet testing negative by RT-PCR were not further analyzed.

Establishment of CLL diagnosis, treatment decisions, review of medical history, and assessment of patient status were performed by the local teams following international guidelines \[[@CR19]\].

Severe COVID-19 was defined as hospitalization and need of oxygen or admission into an intensive care unit; nonsevere/mild COVID-19 was defined as confinement at home or hospitalization without need of oxygen. Hospitalized patients were defined as those with severe COVID-19 and those requiring hospitalization without need of oxygen.

Statistical analysis {#Sec4}
--------------------

Subgroups analyses were performed, stratifying patients based on (1) clinico-biological characteristics (age, comorbidities, gender); (2) severity of COVID-19 (severe vs nonsevere); (3) antileukemic treatment (ongoing or previous last therapy within the last 12 months vs never treated or previous last therapy \> 12 months, considering that therapy-related immunosuppresion after chemoimmunotherapy (CIT) may persist in the first year after discontinuation). Subgroup analyses of patients with severe COVID-19 were carried out to better identify risk in this cohort of patients: these analyses stratified between untreated vs treated patients; and, those on treatment or recently treated vs never treated or off treatment for \>12 months.

Means between groups were compared using independent group *t*-test and the Mann--Whitney test for normally and abnormally distributed data, respectively. Proportions for categorical variables were compared by chi-square or Fisher's test when appropriate. Survival outcomes were analyzed according to the Kaplan--Meier estimator. The analysis was performed using IBM SPSS version 26.0, Microsoft Excel Office 365, and Graphpad Prism v8.4.2.

Results {#Sec5}
=======

Survey results {#Sec6}
--------------

One-hundred and twenty-one investigators from 118 sites completed the survey; most participants were hematologists. Among 121 responders, 58 confirmed the presence of COVID-19 cases in their CLL patient cohort. Most responders were from Europe (74.6%), followed by Asia (13.6%), Latin America (4.2%), Africa (3.4%), Canada (2.5%), and Australia (1.7%). At the time of launching the data collection, we became aware of ongoing US collaborative initiatives on the same topic; therefore, in order to avoid potential redundancy, US sites were intentionally excluded from our survey.

All sites participating in the survey except one (0.8%) reported implementing preventive measures for patients with CLL regarding the SARS-CoV-2 pandemic, applied to all patients with CLL (57.0%) or only those attending the clinic (43.0%). In the vast majority of cases (105/118 sites) these measures were implemented according to national recommendations for the SARS-CoV-2 pandemic. The main actions taken included frequent hand washing and wearing masks and gloves for health care professionals, sanitizers at the entrance of the visiting room, postponing visits, and implementing remote visit platforms. The full list of measures is reported in Supplementary Table [2](#MOESM1){ref-type="media"}.

COVID-19 cases: site and patient disposition {#Sec7}
--------------------------------------------

Among 221 cases with suspected COVID-19 based on presenting symptoms and/or imaging findings, 206 underwent molecular testing (RT-PCR) on nasopharyngeal swabs for SARS-CoV-2; of these, 190 (92.2%) tested positive by RT-PCR and were selected as the study cohort.

Information on the total number of patients followed at each site was available for 47 participating sites, contributing 82.1% of all COVID-19 patients with CLL in our series. Collectively, these sites reported 156 COVID-19 cases among 15,083 (1.0%) patients with CLL attended at the respective institutions. The proportion of patients developing symptomatic COVID-19 requiring hospitalization was 141/15,083 (0.9%).

Patient characteristics, including CLL and treatment status at the time of COVID-19, are shown in Table [1](#Tab1){ref-type="table"}. Median age at COVID-19 diagnosis was 72 years (range 48--94), with the expected male: female ratio of 2.0. At the time of COVID-19, 76% of patients (145/190) carried one or more comorbidities, with a median number of 2 (range 1--9): the most frequent concerned hypertension (78 cases, 54%), cardiovascular diseases (42 cases, 29%), diabetes mellitus (35 cases, 24%), chronic obstructive pulmonary disease (COPD, 9 cases, 6%), other respiratory diseases (21, 14%), other malignancies (18, 12%).Table 1Patients' characteristics.CharacteristicResultMedian age, years (range, years)72 (48--94)Male/female126/64Diagnosis CLL\|MBL (%)183/2 (96) SLL (%)5 (3)Patients with comorbidities at the time of COVID-19 (%)145 (76)Median number of comorbidities (range)2 (1--9)Median time between CLL diagnosis and COVID-19, months (range, months)81 (0--30 years)Type of comorbidities Hypertension (%)78 (54) Diabetes mellitus (%)35 (24) COPD (%)9 (6) Cardiovascular (%)42 (29) Respiratory (%)21 (14) Other malignancies (%)18 (12)CLL treatment history Previously untreated (%)73 (38.6) Received treatment (%)116 (61.4)  1 line of treatment62  2 lines of treatment30  3 lines of treatment15  4 lines of treatment6  \>4 lines of treatment3Missing information1On treatment at the time of COVID-19 (%)65 (34.2%) BTK inhibitor (acalabrutinib, ibrutinib, zanubrutinib) (%)44 (67.7) Venetoclax-based regimens (%)9 (13.8) Idelalisib (%)3 (4.6) Chlorambucil ± obinutuzumab (%)3 (4.6) Bendamustine + rituximab (%)2 (3.1) Other (chemotherapy ± steroids) (%)4 (6.2%)Hypogammaglobulinemia Present (%)89 (57.8) Absent (%)65 (42.2) Missing information36*CLL* chronic lymphocytic leukemia, *SLL* small lymphocytic lymphoma, *MBL* monoclonal B-cell lymphocytosis, *COPD* chronic obstructive pulmonary disease, *BTK* Bruton tyrosine kinase.

Regarding CLL history, 73 (38.4%) patients were previously untreated, whereas 116 (61.1%) had previously received and/or were receiving treatment for CLL (missing information: 1 patient). Number of lines of treatment were: 1 in 62, 2 in 30, 3 in 15, 4 in 6, \>4 in 3 patients. Sixty-five patients (34.2%) were receiving treatment for CLL at the time of COVID-19 diagnosis: 44 were on a BTK inhibitor (ibrutinib 39, acalabrutinib 4, zanubrutinib 1), 9 on venetoclax-based regimens, 3 on idelalisib, 3 on chlorambucil ± obinutuzumab, 2 on bendamustine + rituximab (BR), and 4 on other regimens (steroids and/or chemotherapy, mainly for autoimmune complications). Another 51 patients (26.8%) had been previously treated but were not receiving treatment at the time of COVID-19 diagnosis. Amongst these, 19 (37.3%) had received the following therapies in the previous 12 months: fludarabine, cyclophosphamide, and rituximab (FCR, 5), BR (4), other CITs (4), allotransplant (1), novel agents \[ibrutinib (3), venetoclax (1), idelalisib + rituximab (1); no available information regarding treatment cessation\]. Thirty-two of 51 patients (62.7%) had been treated \>1 year prior to COVID-19 with the following regimens: FCR (10), BR (3), ibrutinib ± rituximab (4), venetoclax (1), other CITs (13), experimental agents (1). Overall, the median time between the last line of treatment and COVID-19 was 20 months (range 13 months to 10 years).

Eighty-nine of 154 patients (57.8%) for whom this information was available had documented hypogammaglobulinemia at the time of COVID-19.

Detailed information about the comorbidity and treatment profiles of the studied patients is given in [Supplementary material](#MOESM1){ref-type="media"} and Supplementary Table [3](#MOESM1){ref-type="media"}.

COVID-19 manifestations and management {#Sec8}
--------------------------------------

Patients with CLL and COVID-19 presented with fever (165/190, 87%) and respiratory symptoms, including cough (93/190, 49%) and dyspnea (92/190, 48%). Other common manifestations included fatigue (32/190, 17%), diarrhea (22/190, 12%), myalgias/arthralgias (19/190, 10%), headache (13/190, 7%), while anosmia/ageusia (5/190, 3%), nausea and vomiting (5/190, 3%), and abdominal pain (3/190, 2%) were rare (Table [2](#Tab2){ref-type="table"}).Table 2Clinical presentation and management of patients with COVID-19.CharacteristicResultSymptomsNo (%) Fever165 (87) Cough93 (49) Dyspnea92 (48) Myalgias/arthralgias29 (15) Nausea and vomiting5 (3) Diarrhea22 (12) Fatigue32 (17) Anosmia/ageusia5 (3) Nasal discharge5 (3) Sore throat8 (4) Abdominal pain5 (3)Management of COVID-19 Confinement at home21 (11) Hospitalization without need of oxygen18 (10) Hospitalization with need of oxygen112 (59) Intensive care39 (20)Pharmacological treatment for COVID-19 Antivirals95 (50) Hydroxychloroquine or similar145 (76) Azithromycin90 (47) Monoclonal antibodies against IL6/IL6R43 (23)COVID-19 outcome Resolution96 (51) Still under medical care37 (19) Death56 (30) Missing1

Twenty-one of 190 patients (11.1%) were managed at home, while 169 (88.9%) required hospitalization, in 112/169 with need of oxygen supplementation, 39 in the intensive care unit. Most patients (168/187, information missing only in 3 cases) received at least 1 pharmacologic treatment for COVID-19, including: hydroxychloroquine or similar (76%), antivirals (50%), azithromycin (47%), anti-IL6 and/or anti-IL6R monoclonal antibodies (23%) (Table [2](#Tab2){ref-type="table"}).

Among 65 patients receiving treatment for CLL at the time of COVID-19, 54 (83%) stopped treatment (acalabrutinib 4/4, ibrutinib 30/39, zanubrutinib 1/1, idelalisib 2/3, venetoclax ± rituximab 9/9, CIT, and/or steroids 8/9). Among those who continued treatment as planned, nine were on ibrutinib, one on idelalisib and one was receiving steroid treatment due to autoimmune hemolytic anemia. Of 45 patients with severe COVID-19 under CLL-specific treatment, 31 were receiving BTK inhibitors: the infection outcome in these 31 patients was resolution (14), still unresolved (4), death (13). In 13 patients with less severe COVID-19 on BTK inhibitors, the outcome was resolution (7), still unresolved (4) and death (1), with 1 missing.

After a median follow-up of 23 days (range 2--86), 96 patients completely recovered (median time to recovery 22.5 days, range 2--86), 37 were still under medical care and 56 died; infection outcome was missing only in 1 case (Table [2](#Tab2){ref-type="table"}). Median OS was not reached, with 69% of patients alive at 30 days (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Overall survival in our patient cohort (*n* = 190).Overall survival of patients with CLL and COVID-19 in days from suspected COVID-19 until last follow-up.

Predictors of outcome of COVID-19 in CLL {#Sec9}
----------------------------------------

Comparisons between 151 patients who required hospitalization with oxygen support and/or were admitted to the intensive care unit, thus experiencing severe COVID-19, versus 39 patients confined at home and/or requiring hospitalization without need of oxygen, therefore, considered to have a less severe infection course, revealed no differences regarding gender, the presence of three or more comorbidities or hypogammaglobulinemia (Table [3](#Tab3){ref-type="table"}).Table 3Patients' disposition based on COVID-19 severity.VariableSevere COVID-19 (*n* = 151)Nonsevere COVID-19 (*n* = 39)*p*Age ≥65 years (%)112 (74.2)17 (43.6)\<**0.05** \<65 years (%)39 (25.8)22 (56.4)Gender Male (%)98 (64.9)28 (71.8)n.s. Female (%)53 (35.1)11 (28.2)Median time between CLL diagnosis and COVID-198871n.s.Treatment for CLL Untreated (%)64 (42.7)9 (23.1)\<**0.05** Treated (%)86 (57.3)30 (76.9)Treatment during the last 12 months or ongoing Yes (%)60 (39.7)24 (61.5)\<**0.05** Untreated or treated \> 12 months before (%)91 (60.3)15 (38.5)Treatment 1 previous line (%)48 (31.8)14 (35.9)n.s. 2 or more previous lines (%)38 (25.2)16 (41.0)Comorbidities \>246 (30.5)12 (30.8)n.s. ≤2105 (69.5)27 (69.2)Hypogammalobulinemia Yes66 (55.0)23 (67.6)n.s. No54 (45.0)11 (32.4)Outcome Alive (%)96 (63.6)37 (97.4)\<**0.00001** Dead (%)55 (36.4)1 (2.6)Bold values indicate statistical significance *p* \< 0.05.

In contrast, these comparisons revealed significant differences regarding age, CLL treatment history and mortality. In particular, 112/151 (74.2%) in the severe group were ≥65 years compared to only 17/39 (43.6%) in the less severe group (*p* \< 0.05). Moreover, significantly (*p* \< 0.05) more patients (91/151, 60.3%) in the severe COVID-19 group were off treatment within the last year or had never received treatment for CLL compared to less severe cases (15/39, 38.5%). In addition, hospitalization rate due to COVID-19 was significantly different depending on the type of treatment. In particular, 27/1729 (1.6%) on ibrutinib were hospitalized because of COVID-19, 8/442 (1.8%) on venetoclax and 18/428 (4.2%) on CIT with a higher risk in those treated with CIT compared to ibrutinib (odds ratio (OR) 2.77, 95% CI 1.51--5.10, *p* \< 0.01) and venetoclax (OR 2.77, 95% CI 1.02--5.54, *p* \< 0.05). Moreover, hospitalization rate for severe COVID-19 was lower for those on ibrutinib (OR 0.44 \[95% CI 0.20--0.96\] *p* \< 0.05) as compared to those receiving any other CLL-specific treatment or off treatment.

The disposition of patients who died because of COVID-19 is reported in Table [4](#Tab4){ref-type="table"}. Unsurprisingly, the death rate was significantly (*p* \< 0.00001) higher in severe (55/151, 36.4%) versus less severe COVID-19 cases (1/38 cases with available data; 2.6%). Of note, however, amongst those who died because of severe COVID-19, age was not found to associate with mortality risk \[16/61 patients (26.2%) \<65 years died versus 40/129 (31%) patients ≥65 years; *p* = non significant\].Table 4Characteristics of CLL patients who died of COVID-19 (*n* = 56).CharacteristicResultMedian age, years (range, years)75.5 (51--91)Male/female38/18Diagnosis CLL (%)54 (96.4) SLL (%)1 (1.8) MBL (%)1 (1.8)Patients with comorbidities at the time of COVID-19 (%)46 (82.1)Median number of comorbidities (range)2 (1--9)Type of comorbidities Hypertension (%)26 (46.4) Diabetes mellitus (%)10 (17.9) COPD (%)4 (7.1) Cardiovascular (%)10 (17.9) Respiratory (%)6 (10.7) Other malignancies (%)4 (7.1)CLL treatment history Previously untreated (%)18 (32) Received treatment (%)38 (68)  1 line of treatment21  2 lines of treatment8  3 lines of treatment5  4 lines of treatment3  \>4 lines of treatment1On treatment at the time of COVID-19 (%)19 (34) BTK inhibitor (acalabrutinib, ibrutinib)12 Venetoclax-based regimens1 Idelalisib1 Chemoimmunotherapy3 Corticosteroids1 Other (chemotherapy ± steroids)1Hypogammaglobulinemia Present (%)32 (64) Absent (%)18 (36) Missing information6Pharmacological treatment for COVID-19 Antivirals (%)30 (54) Hydroxychloroquine or similar (%)38 (68) Azithromycin (%)18 (32) Monoclonal antibodies against IL6/IL6R (%)9 (16)Management Confinement at home1 (1.8) Hospitalization without need of oxygen0 Hospitalization with need of oxygen39 (69.6) Intensive care16 (28.6)*CLL* chronic lymphocytic leukemia, *SLL* small lymphocytic lymphoma, *MBL* monoclonal B-cell lymphocytosis, *COPD* chronic obstructive pulmonary disease, *BTK* Bruton tyrosine kinase.

Discussion {#Sec10}
==========

To the best of our knowledge, we present here the largest European series of patients with CLL infected by SARS-CoV-2 and experiencing COVID-19. Among the European cases (96.8% of the total) included in this project, almost 90% originate from Italy and Spain, hence mirroring the dynamics of the SARS-CoV-2 pandemic in Europe with Italy being the first country in number of infected individuals followed by Spain, with a lower incidence, e.g., in Greece or Northern countries.

Patients were strictly selected and included in this retrospective analysis only if they had a confirmed COVID-19 diagnosis by molecular testing and were followed at the participating sites. In order to avoid the possibility of ascertainment biases due to the fact that in most countries only patients with relevant symptoms are tested for SARS-CoV-2, we tried to draw conclusions in particular from cases requiring hospitalization with or without oxygen support and/or intensive care admission, making it more comparable in all different national situations.

In line with previous reports in the general population, also in our cohort older age was associated with more severe COVID-19 manifestations: in particular, the group of patients admitted to the hospital requiring oxygen and/or ventilatory support was enriched for patients ≥65 years compared to those with milder disease. The presence of three or more comorbidities was not significantly different in patients hospitalized with severe versus nonsevere disease; moreover, the presence of hypogammaglobulinemia, a frequent laboratory finding in CLL, did not show a relevant impact on the clinical course of COVID-19 patients, probably underscoring the relevance of the inflammatory reaction rather than the viral replication (and the capacity to clear it by antibody-mediated immune response) in shaping the severity of the disease.

The potential impact of CLL-specific treatments on the course of COVID-19 still needs to be fully elucidated, with international guidelines suggesting careful evaluation of pros/cons of treatment interruption, in particular in patients on targeted agents \[[@CR20]\]. Taking into consideration the potential long-term effect on the immune system and the risk of infections (up to 12 months) particularly for patients treated with CIT, we grouped together patients who were on ongoing or had received recent (\<12 months) therapies vs patients with no treatments in their lifetime or in the past previous year. Relevant to mention in this respect, our cohort of COVID-19 patients is enriched for patients receiving treatment for CLL compared to a standard population (indeed 2679/15,083, 17.8% were on treatment at participating sites, while 65/190, 34.2% COVID-19 cases were treated). Interestingly, patients under ibrutinib less likely needed hospitalization suggesting a diverse effect of the antileukemic treatments, probably due to a different impact on the immune deficiency and/or dysregulation. Along the same direction, we here report that patients on recent or ongoing treatment were more likely to have a milder COVID-19 compared to those with severe disease who in the vast majority were on a watch and wait follow-up. It is important to note that a relevant proportion of patients included into the study were on BTK inhibitors but, due to limited numbers of patients treated with other therapies, our study does not allow reaching firm conclusions on potential differences between the different types of treatment (BTK inhibitors vs venetoclax-based regimens vs CIT and/or steroids). Altogether, these data seem to further underscore the possible protective role of specific targeted therapies against a dismal evolution of the SARS-CoV-2 infection \[[@CR17], [@CR21]\].

Considering the median age of 72 years at the time of COVID-19 occurrence and the presence of at least one comorbidity in \~75% of our patients (median number of comorbidities 2), the high mortality rate (55/169, 32.5%) among the hospitalized patients reported in this cohort comes as no surprise, though it is apparently higher than expected in the general population (e.g., 13.4% amongst the general population in Italy) (<https://www.epicentro.iss.it/coronavirus/>). However, if we consider only patients with CLL ≥ 70 years of age, the percentage (36/105, 34.3%) is not considerably different from that of normal individuals \>70 years (25.5%, <https://www.epicentro.iss.it/coronavirus/>) \[[@CR18]\]. The difference in the overall mortality rate was seen in all age groups, with young patients (\<65 years) succumbing to the disease at rates similar to those of the elderly (26.2% and 31.0%, respectively), though the elderly patients were more likely to experience severe COVID-19, as reported above. This evidence is pointing to the fact that when severe COVID-19 occurs, it is probably the underlying leukemic disease with the typical immune dysregulation that predisposes to a dismal outcome, levelling off the death risk and overcoming the effect of age and other comorbidities.

Along the same line of reasoning, the apparent higher rate of hospitalization in our cohort (141/15,083, 0.9%) compared to a much lower rate for example in the Italian population (0.24%) (<https://www.epicentro.iss.it/coronavirus/>) may simply be due to older age and higher comorbidity burden of the patients with CLL here reported.

Our study has some limitations: (1) the large majority of CLL cases was provided by only two countries (Italy and Spain), making the case series possibly not fully representative of the COVID-19 course in other countries; (2) cases with more severe clinical presentations had a higher probability of being included in the study due to having a confirmed COVID-19 diagnosis, making it difficult to define the prevalence, morbidity and mortality compared to the general population, that indeed was the aim of our study. To mitigate at least in part these limitations, we restricted our analyses to hospitalized patients that are more objectively recorded in all different national situations. Despite these limitations, our series thoroughly describes COVID-19 outcome in a large cohort of patients with CLL in Europe and suggests that these patients may be at a higher risk of developing symptomatic COVID-19 and of succumbing to the disease due to the underlying leukemia, while at least some CLL treatments may favorably influence COVID-19 course. This finding warrants further investigation to understand the potential protective role of CLL treatment, in particular with BTK inhibitors, on the clinical course, morbidity and mortality of COVID-19 patients with CLL.
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